Microdosing psilocybin: what placebo-controlled studies have and have not shown

Microdosing psilocybin means regularly taking a very small amount of a psychedelic, often described as below the level that produces obvious effects. It has attracted attention because of enthusiastic personal reports. The research question is narrower: when you compare microdosing with an inactive capsule, under conditions where people do not know which they got, do the reported benefits remain? The most direct answer from controlled studies so far is "mostly not", with real caveats about how much those studies can settle (Szigeti et al., 2021; Cavanna et al., 2022; Marschall et al., 2022).

This page describes what these studies did and found. It is not medical advice, it does not describe how anyone should use anything, and it deliberately leaves out dose amounts and schedules. Nothing here is a claim that microdosing treats any condition.

What have placebo-controlled microdosing studies found?

The table puts the main psilocybin-related studies side by side. The designs are very different, which is part of why the field is hard to summarise: some are laboratory studies, some are semi-naturalistic, and one is a citizen-science project with no clinic at all.

Taken together, no single controlled study shows a broad benefit to well-being or cognition, and the clearest recurring result is that participants often knew what they had taken. The one signal that has survived adjustment so far is narrow: a quality-of-thinking measure in creativity tasks in one pooled set of trials. Its authors do not claim it matters in daily life.

What was the self-blinding citizen-science study?

Szigeti and colleagues invited people already planning to microdose to put a placebo control into their own routine, following online instructions and without clinical supervision. 191 participants completed it, which the authors described as the largest placebo-controlled trial on psychedelics to that date. Everyone improved on the psychological outcomes over the 4-week period. The placebo group improved just as much, and there were no significant differences between groups on those outcomes (Szigeti et al., 2021).

The authors state their own limits plainly. The design is part-controlled and part-observational, so it is stronger than a plain survey but weaker than a clinical trial, and the nature, purity and amount of what participants used were not verified. In the full text, psilocybin mushrooms were used by 23% of the sample, so it should not be read as a psilocybin-only study. Some small differences in acute effects and anxiety favoured the active condition, but the authors say these can be explained by participants correctly guessing what they had taken (Szigeti et al., 2021).

Is microdosing just a placebo effect?

Two things can be true at once. The expectation that something will help can produce real changes in how people feel, and those changes show up in placebo groups too. That is the central result of the self-blinding study, and Cavanna and colleagues reached a similar conclusion about psilocybin mushrooms, writing that expectation underlies at least some of the anecdotal benefits (Cavanna et al., 2022).

But a 2024 rapid review in the Journal of Psychopharmacology argues that "it is just a placebo" is itself premature. Polito and Liknaitzky identified 19 placebo-controlled microdosing studies (LSD and psilocybin), found changes relative to placebo in neurobiology, physiology, subjective experience, affect and cognition, and listed eight reasons the placebo claim goes beyond the evidence, among them small numbers of controlled studies, small samples, few doses tested, possibly too-small doses and non-clinical populations. They concluded that it is not yet possible to determine whether microdosing is a placebo (Polito and Liknaitzky, 2024).

These positions are less opposed than they sound. Both say the controlled evidence is thin and that the strong claims in either direction are not yet supported. What the controlled studies do not support is the specific popular claim that microdosing reliably improves mood, focus or well-being beyond what expectation alone produces.

Why is blinding so hard in microdosing research?

A compound that is described as sub-perceptual may still produce enough noticeable change for some people to guess correctly. Cavanna's group found acute effects were more intense with the active material, but only in participants who correctly identified their condition (Cavanna et al., 2022). Marschall's group, in an exploratory analysis, reported that participants broke blind in the second block (Marschall et al., 2022). By contrast, the two 2026 trials reported by Prochazkova and colleagues said participants remained effectively blinded (Prochazkova et al., 2026). So blinding success varies between studies, and the results are interpreted differently depending on it.

What do observational microdosing studies show?

Observational studies follow people who choose to microdose, with or without a comparison group, and ask them how they feel. These are the studies that most often report benefits. Rootman and colleagues followed 953 psilocybin microdosers and 180 non-microdosing comparators for about 30 days and reported small-to-medium improvements in mood and mental health, which they described as consistent across gender, age and presence of mental health concerns (Rootman et al., 2022). The same journal has also published an author correction to that paper; we did not review what it changed, so check it if you rely on specific figures (author correction).

A 2026 analysis of a naturalistic international survey (N = 1,435) found higher self-ratings of well-being, productivity, creativity, connectedness, contemplation and focus on microdosing days than on non-microdosing days. Its authors urged caution because the study is observational and exploratory (St Pierre et al., 2026).

The key limit is that people who choose to microdose, and who expect to benefit, are a self-selected group, and they know when they have taken something. That is exactly the setup in which expectancy has the most room to operate. The self-blinding study's authors make the same point about earlier observational work (Szigeti et al., 2021). Observational data are useful for generating questions and for describing what people report, not for establishing that the substance caused the change.

Which outcomes have studies actually measured?

• Self-reported mood, anxiety, depression and stress scales (Szigeti, Marschall, Rootman, Prochazkova).
• Creativity tasks, split into divergent thinking (generating many ideas, originality) and convergent thinking (finding a single correct solution) (Cavanna, Prochazkova).
• Cognitive tasks such as attention, memory and cognitive control (Cavanna, Prochazkova).
• Acute subjective experience, such as intensity of effects, mood and energy on dosing days (Szigeti, Cavanna).
• Brain-activity recordings such as EEG, where Cavanna's group reported reduced theta power (Cavanna).
• Emotion-processing tasks and self-reported interoceptive awareness (Marschall).

A methodological point raised in the literature is that outcome measures designed for full psychedelic experiences may be poorly suited to detect very small effects. Sanz and colleagues, working with Cavanna's group, reported that features of unconstrained speech could distinguish a microdose condition from placebo, which they presented as evidence that measurement tools matter (Sanz et al., 2022). That is a laboratory signal, not evidence of benefit.

What is known about the safety of psilocybin microdosing?

Less than most people assume. A 2026 systematic review of psilocybin mushroom and truffle microdosing included 11 studies and 3,262 adults, rated the certainty of the evidence as low, said a causal effect cannot be inferred, and noted that most included studies did not report adverse events at all. Among those that did, events were mostly mild. The authors called for mandatory adverse-event reporting in future work (Page et al., 2026).

One specific concern is theoretical rather than demonstrated. Psychedelics bind the serotonin 2B receptor, and strong, chronic activation of that receptor is known to cause heart-valve disease with some other drugs, such as fenfluramine. Whether that applies to very low doses of psilocybin taken repeatedly is unknown. A 2025 mouse study of repeated low-dose LSD found no evidence of ventricular or valvular remodelling, and its authors reported no significant difference in affinity or potency at that receptor between LSD, psilocybin and a fenfluramine metabolite (Effinger et al., 2025). A 2026 cross-sectional analysis in a large US cohort found modestly higher odds of valvular heart disease among people with lifetime hallucinogen use after adjustment, but the authors called it exploratory, it did not measure microdosing specifically, and it requires confirmation (Yang et al., 2026). A 2026 narrative review concluded that long-term cardiac and psychiatric safety of microdosing remains unresolved (Kéri, 2026).

Put plainly, there is no demonstrated valvular harm from microdosing psilocybin in humans, and there is no study long and large enough to rule it out. Neither statement should be read as reassurance or as a warning, only as a gap. Everyday risk information is on our safety page.

Are there newer or planned trials?

The 2026 Prochazkova papers are the most recent controlled psilocybin results we could verify. We also found a 2025 protocol, posted as a preprint, for a planned phase II placebo-controlled trial of microdosing psilocybin in people with major depressive disorder. A protocol is a plan, not a result, and the preprint has not been peer reviewed (Beidas et al., 2025). We have not located results from it.

Is microdosing psilocybin legal in Canada?

As of 24 October 2026, Health Canada's page (last modified 20 October 2026) states that the production, sale and possession of magic mushrooms are illegal in Canada and that there are no approved therapeutic products containing psilocybin in Canada or elsewhere (Health Canada). The size of a dose does not change that status. For the detail, read are magic mushrooms legal in Canada?, and check the official page for any change.

What is still unknown?

• Whether any real, durable effect exists beyond expectancy. Authors on both sides say the controlled studies are too few and too small to say.
• Whether the studies tested the right doses, durations and people. Marschall's authors say a sample with clinical-range anxiety and depressive symptoms is still needed.
• How to blind a microdosing study properly, and how to measure expectancy reliably before it starts.
• Whether the small creativity signal in pooled trials replicates and whether it matters outside a test.
• Long-term cardiac and psychiatric safety with repeated use, which no study yet addresses.
• How results from psilocybin truffles, mushrooms and LSD map onto one another, since the compounds, preparations and studies are mixed in the literature.

For background on the compound, see what psilocybin is and what magic mushrooms are. For research at full doses in supervised settings, which is a separate question with separate evidence, read our summary of psilocybin depression trials.

Shroomverse sells mushroom products. This article is general information about clinical research. It is not medical, legal or purchasing advice, and it does not recommend any product.